Close Menu

Veracyte

The firm will use the proceeds for working capital and other general corporate purposes, with the potential to acquire or invest in complementary businesses, technologies, or assets. 

The index significantly outperformed the Dow Jones, the Nasdaq, and the Nasdaq Biotechnology Index in July.

For the three months ended June 30, the genomic testing firm reported total revenues of $20.7 million.

MaviDx will develop, validate, secure regulatory approvals for, and commercialize its SARS-CoV-2 and other infectious disease tests, including for influenza, on Veracyte's nCounter system.

The GenomeWeb Index rose more than 9 percent in May, following an 18 percent climb in April, a marked contrast to its negative performance in February and March.

The agreement marks Veracyte's first deal to expand the testing menu on the nCounter instrument since it acquired the rights to the platform from NanoString in December.

For the three months ended Mar. 31, the firm reported total revenues of $31.1 million compared to $29.5 million in Q1 2019, beating analysts' average estimate of $30.6 million.

Veracyte has obtained rights to a 52-gene signature developed by Yale researchers to predict disease progression in patients with idiopathic pulmonary fibrosis.

The company expects Q1 revenues to be in the range of $30.5 million to $31.5 million compared to $29.5 million in the year ago period, due to an increase in its testing volume.

Pages

Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.

Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.

The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.

This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.